These underappreciated dividend payers offer yields above 4% at recent prices.The past year has been terrific for most stocks. The S&P 500 index rose 27.5% during the 12 months ended Aug. 26.It's always nice to see the value of your portfolio rise during a bull market, but it also makes it hard to find stocks to buy at reasonable valuations.Investors seeking reliable dividend stocks that still look like bargains will be glad to know that not all of the S&P 500's components have had a great year. Pfizer (PFE ...

Core Viewpoint - Bristol Myers (BMY) has received FDA acceptance for its supplemental Biologics License Application (sBLA) for the immunotherapy drug Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC) [1] Company Summary - The sBLA is based on the late-stage CheckMate-9DW study, which demonstrated a statistically significant improvement in overall survival for the Opdivo plus Yervoy combination compared to Lenvima or Nexavar [1] - A final decision from the FDA is expected on April 21, 2025 [1] - Opdivo is already indicated in the U.S. for HCC patients previously treated with Nexavar under accelerated approval [2] - Bristol Myers' shares have decreased by 5.6% year-to-date, while the industry has grown by 1.1% [2] Industry Summary - HCC is the most common type of primary liver cancer, accounting for 75-85% of liver cancers, and is often diagnosed at advanced stages with limited treatment options [2] - The European Medicines Agency (EMA) has validated Bristol Myers' type II variation application for the Opdivo/Yervoy combination as a potential first-line treatment for advanced HCC [5] - Competitors in the HCC market include AstraZeneca, which has an approved combination therapy of Imfinzi (durvalumab) and Imjudo (tremelimumab) for first-line treatment of advanced HCC [6]

Bristol Myers Squibb (BMY) announced that the European Medicines Agency (“EMA”) has validated its type II variation application to expand the indication for CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).The application seeks to expand Breyanzi’s label to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.Validation of the application confirms th ...

With yields above 4%, these stocks could do a lot to boost your passive income streamThe S&P 500 index is up by about 16% so far this year. Many of the index's dividend payers have raised their payouts, but not nearly as much as their stock prices have risen. As a result, the average dividend-paying stock in the benchmark index offers a paltry 1.3% yield at recent prices.Luckily, there are still a handful of top dividend payers trading for low enough prices to offer high yields. Here's why they could be gre ...

Core Viewpoint - Bristol Myers Squibb (BMS) has faced challenges over the past five years, including unimpressive financial results and significant patent expirations, but the company may see a turnaround by 2029 if it effectively navigates these challenges [1] Financial Performance - In Q2, BMS reported a revenue increase of nearly 9% year over year, reaching $12.2 billion, marking its best top-line growth in about three years [2] - The best-selling products during this period were Eliquis, generating $3.4 billion in revenue (up 7% year over year), and Opdivo, with sales of $2.4 billion (up 11% year over year), together accounting for 47.6% of total revenue [3] Patent Cliffs and Future Revenue - Both Eliquis and Opdivo are set to lose patent protection by the end of 2029, which is expected to lead to a decline in revenue [3] - BMS anticipates over $25 billion in revenue from its new product portfolio by 2030, supported by ongoing approvals and clinical trials [4] New Product Pipeline - BMS has received several new approvals since 2019, including Reblozyl ($425 million in Q2, 82% growth), Opdualag ($235 million, 53% growth), and Camzyos ($139 million, 202% growth) [4] - A subcutaneous version of Opdivo is expected to target 65% to 75% of its indications in the U.S., helping to mitigate losses from the upcoming patent cliff [5] Investment Outlook - The company's performance is expected to improve over the next five years, with a strong commitment to increasing dividends, having raised payouts for 15 consecutive years [6] - The forward dividend yield is currently at 5.1%, with a conservative cash payout ratio of just under 37%, positioning BMS as a solid blue-chip dividend stock for long-term investment [6]

Investors might want to bet on Bristol Myers Squibb (BMY) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive es ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this biopharmaceutical company have returned +12.2%, compared to the Zacks S&P 500 composite's -2.9% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Bristol Myers falls in, has lost 0.1%. The key question now is: What could be the stoc ...

WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis. “Given their leadership in cell therapy ...

Bristol Myers Squibb Company (BMY) has regained some of the lost territories in the past month, giving anxious investors a ray of hope. This biotech giant has been facing a few challenges for quite some time now.Shares of BMY have risen 16.4% in a month against the industry’s decline of 0.7%. The stock has also outperformed the sector and the S&P 500 in this period.The rally came after the company reported better-than-expected second-quarter results in July. Upside in blood-thinner drug Eliquis and immuno-o ...